Effectiveness and Impact of Autumn 2023 COVID‐19 Vaccination in Preventing Hospitalizations in Navarre, Spain, October 2023 to September 2024
Influenza and Other Respiratory Viruses · 2025
DOI: 10.1111/irv.70163 ↗Kurz gefasst
Fachartikel in der Zeitschrift Influenza and Other Respiratory Viruses, 2025. Verfasst von Iván Martínez-Baz und 9 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Salud Pública de Navarra, Pamplona, Spain. Hauptthemen laut MEDLINE: Hospitalization, COVID-19, COVID-19 Vaccines, Vaccine Efficacy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III with the European Fund for Regional Development, VEBIS project, European Centre for Disease Prevention and Control.
Abstract (Originalsprache)
Objective
We aimed to estimate autumn 2023 COVID‐19 vaccine effectiveness (CVE) in preventing hospitalizations due to COVID‐19 until September 2024.
Methods
We performed a test‐negative case–control study nested in the cohort of adults aged ≥ 45 years with indication of autumn 2023 COVID‐19 vaccination in Navarre, Spain. The study included patients hospitalized for severe acute respiratory infection (SARI) and tested by polymerase chain reaction between October 2023 and September 2024. The COVID‐19 vaccination statuses in the current and previous seasons were compared between confirmed COVID‐19 cases and test‐negative controls. CVE was estimated as (1 − adjusted odds ratio) × 100.
Results
Of 4051 SARI hospitalized patients included in the study, 474 (12%) were confirmed for COVID‐19. CVE to prevent COVID‐19 hospitalizations was 32% (95% confidence interval [CI], 11%–48%) on average for the year and 38% (95% CI, 17%–54%) among people aged ≥ 65 years. However, estimates for current‐season vaccination were 51% (95% CI, 30%–66%), 50% (95% CI, 16%–70%), and 0% (95% CI, −42% to 30%) for 7 to 89, 90 to 179, and ≥ 180 days between vaccination and COVID‐19 diagnosis, respectively. The residual effect of previous‐season vaccination was not statistically significant (14%; 95% CI, −20% to 39%). CVE was moderate in preventing COVID‐19 hospitalizations between October 2023 and March 2024 (50%; 95% CI, 28%–65%), and null between April and September 2024 (6%; 95% CI, −41% to 38%). The vaccine averted 19% of COVID‐19 hospitalizations. On average, 963 doses of vaccine were necessary to prevent one COVID‐19 hospitalization.
Conclusions
CVE was moderate in preventing COVID‐19 hospitalizations during the 2023–2024 season, but decreased 6 months after vaccination.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Instituto de Salud Pública de Navarra, Pamplona, Spain.
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
- Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
- Clinical Microbiology Department, Hospital Universitario de Navarra, Pamplona, Spain.
- Clinical Microbiology Department, Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain.
ORCID-Profile: Iván Martínez-Baz, Camino Trobajo-Sanmartín, Noelia Vera-Punzano, María Eugenia Portillo, Guillermo Ezpeleta, Jesús Castilla
Förderung
- Instituto de Salud Carlos III with the European Fund for Regional Development
- VEBIS project
- European Centre for Disease Prevention and Control
Zitieren
APA
Martínez-Baz, I., Trobajo-Sanmartín, C., Fernández-Huerta, M., Navascués, A., Echeverria, A., Egüés, N., Vera-Punzano, N., Portillo, M. E., Ezpeleta, G., & Castilla, J. (2025). Effectiveness and Impact of Autumn 2023 COVID‐19 Vaccination in Preventing Hospitalizations in Navarre, Spain, October 2023 to September 2024. Influenza and Other Respiratory Viruses. https://doi.org/10.1111/irv.70163
Vancouver
Martínez-Baz I, Trobajo-Sanmartín C, Fernández-Huerta M, Navascués A, Echeverria A, Egüés N, et al. Effectiveness and Impact of Autumn 2023 COVID‐19 Vaccination in Preventing Hospitalizations in Navarre, Spain, October 2023 to September 2024. Influenza and Other Respiratory Viruses. 2025. doi:10.1111/irv.70163
BibTeX
@article{MartnezBaz2025,
author = {Martínez-Baz, Iván and Trobajo-Sanmartín, Camino and Fernández-Huerta, Miguel and Navascués, Ana and Echeverria, Aitziber and Egüés, Nerea and Vera-Punzano, Noelia and Portillo, María Eugenia and Ezpeleta, Guillermo and Castilla, Jesús},
title = {Effectiveness and Impact of Autumn 2023 COVID‐19 Vaccination in Preventing Hospitalizations in Navarre, Spain, October 2023 to September 2024},
journal = {Influenza and Other Respiratory Viruses},
year = {2025},
doi = {10.1111/irv.70163}
}
EUVIMED